List view / Grid view
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
A research team based at Skoltech in Russia has developed an artificial intelligence-driven solution for highly accurate detection of efficacious binding sites to expedite drug discovery.
A new study in the US has used a computer model to reveal the mechanism of action of lipoprotein-associated phospholipase A2 – a biomarker for cardiovascular disease.
The new study identified PDZ-binding kinase (PBK) as a promising target for pulmonary hypertension and assessed two PBK inhibitors.
Researchers developed a platform that can rapidly screen thousands of compounds to identify potential antiviral drugs to treat coronaviruses.
The study reveals the biological mechanism that causes nerve destruction in amyotrophic lateral sclerosis (ALS), potentially leading to treatments that reverse the disease.
The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.
Scientists identified three prototypical RNA-expression states and revealed differences in their susceptibility to a variety of cancer drugs.
The new research shows how interleukin-17a (IL-17a) can alter the trajectory of immune system development and cause gut inflammation.
Scientists have found that SARS-CoV-2 can knock out an important molecular pathway linked to an immune complex called MHC class I.
Scientists identify a drug candidate to minimise erratic muscle movements, called dyskinesia, associated with Parkinson’s disease.
A novel antiviral drug called thapsigargin (TG) blocked COVID-19 infection in cells, including all new variants, in a pre-clinical study.
Researchers discover a new precision strategy to hinder the infection of the coronavirus, leading to the filing of a new drug patent.
Scientists develop organoid models of neuroendocrine prostate cancer to study EZH2 inhibitors and reveal a potential new target.
The study is the first in-depth look at links between COVID-19 severity and gene expression in immune cells and may guide future therapies.
The CRISPR-based therapy called EBT-101 excised HIV proviral DNA from the genomes of different cells and tissues in human cells and mice.
